BMJ Best Practice

参考文献

关键文献

Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am. 2002;29:1-20.

Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353:275-285.

Love SM, Gelman RS, Silen W. Sounding board. Fibrocystic "disease" of the breast--a nondisease? N Eng J Med. 1982;307:1010-1014.

Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.

Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.

参考文章

1.  Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am. 2002;29:1-20.

2.  Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353:275-285.

3.  Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev. 1997;19:310-327.

4.  Sarnelli R, Squartini F. Fibrocystic condition and "at risk" lesions in asymptomatic breasts: a morphologic study of postmenopausal women. Clin Exp Obstet Gynecol. 1991;18:271-279.

5.  Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev. 1999;8:123-130.

6.  Wang DY, Fentiman IS. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat. 1985;6:5-36.

7.  Love SM, Gelman RS, Silen W. Sounding board. Fibrocystic "disease" of the breast--a nondisease? N Eng J Med. 1982;307:1010-1014.

8.  Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001;61:2537-2541.

9.  Duffy SW, Roberts MM, Elton RA. Risk factors relevant to cystic breast disease: a case-control study. J Epidemiol Community Health. 1983;37:271-273.

10.  Cole P, Elwood JM, Kaplan SD. Incidence rates and risk factors of benign breast neoplasms. Am J Epidemiol. 1978;108:112-120.

11.  Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 2008;100:563-571.

12.  Cady B, Steele GD Jr, Morrow M, et al. Evaluation of common breast problems: guidance for primary care providers. CA Cancer J Clin. 1998;48:49-63.

13.  Seltzer MH. Breast complaints, biopsies, and cancer correlated with age in 10,000 consecutive new surgical referrals. Breast J. 2004;10:111-117.

14.  Davies EL, Gateley CA, Miers M, et al. The long-term course of mastalgia. J R Soc Med. 1998;91:462-464.

15.  Tang SS, Twelves DJ, Isacke CM, Gui GP. Mammary ductoscopy in the current management of breast disease. Surg Endosc. 2011;25:1712-1722.

16.  Newman HF, Klein M, Northrup JD, et al. Nipple discharge. Frequency and pathogenesis in an ambulatory population. N Y State J Med. 1983;83:928-933.

17.  Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146-151.

18.  Gemignani ML. Breast cancer screening: why, when, and how many? Clin Obstet Gynecol. 2011;54:125-132.

19.  Horrobin DF, Manku MS. Premenstrual syndrome and premenstrual breast pain (cyclical mastalgia): disorders of essential fatty acid (EFA) metabolism. Prostaglandins Leukot Essent Fatty Acids. 1989;37:255-261.

20.  Pruthi S, Wahner-Roedler DL, Torkelson CJ, et al. Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study. Altern Med Rev. 2010;15:59-67.

21.  Fentiman IS, Caleffi M, Hamed H, et al. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial. Br J Surg. 1988;75:845-846.

22.  Parlati E, Polinari U, Salvi G, et al. Bromocriptine for treatment of benign breast disease. A double-blind clinical trial versus placebo. Acta Obstet Gynecol Scand. 1987;66:483-488.

23.  Mansel RE, Wisbey JR, Hughes LE. Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease. Lancet. 1982;1:928-930.

24.  Smith RL, Pruthi S, Fitzpatrick LA. Evaluation and management of breast pain. Mayo Clin Proc. 2004;79:353-372.

25.  Rosolowich V, Saettler E, Szuck B, et al. Mastalgia. J Obstet Gynaecol Can. 2006;28:49-71.

26.  Basch E, Bent S, Collins J, et al. Flax and flaxseed oil (Linum usitatissimum): A review by the natural standard research collaboration. J Soc Integr Oncol. 2007;5:92-105.

27.  Murshid KRA. Review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options. J Taibah Uni Med Sci. 2011;6:1-18.

28.  Vargas HI, Vargas MP, Gonzalez KD, et al. Outcomes of sonography-based management of breast cysts. Am J Surg. 2004;188:443-447.

29.  Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-237.

30.  Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.

31.  Vargas HI, Romero L, Chlebowski RT. Management of bloody nipple discharge. Curr Treat Options Oncol. 2002;3:157-161.

32.  Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of Mastalgia: a meta-analysis of randomised trials. Breast. 2007;16:503-512.

33.  Vargas HI, Vargas MP, Eldrageely K, et al. Outcomes of clinical and surgical assessment of women with pathological nipple discharge. Am Surg. 2006;72:124-128.

34.  Kessler JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J. 2004;10:328-336.

35.  Ghent WR, Eskin BA, Low DA, et al. Iodine replacement in fibrocystic disease of the breast. Can J Surg. 1993;36:453-460.

36.  Bevers TB. Breast awareness: a shift in the paradigm of breast self-examination. J Natl Compr Canc Netw. 2009;7:1042-1043.

37.  Thornton H, Pillarisetti RR. 'Breast awareness' and 'breast self-examination' are not the same. What do these terms mean? Why are they confused? What can we do? Eur J Cancer. 2008;44:2118-2121.

使用此内容应接受我们的免责声明